DZ3197A1 - Acides aminés bicycliques utilises comme agents pharmaceutiques. - Google Patents

Acides aminés bicycliques utilises comme agents pharmaceutiques.

Info

Publication number
DZ3197A1
DZ3197A1 DZ003197A DZ003197A DZ3197A1 DZ 3197 A1 DZ3197 A1 DZ 3197A1 DZ 003197 A DZ003197 A DZ 003197A DZ 003197 A DZ003197 A DZ 003197A DZ 3197 A1 DZ3197 A1 DZ 3197A1
Authority
DZ
Algeria
Prior art keywords
amino acids
pharmaceutical agents
acids used
bicyclic amino
bicyclic
Prior art date
Application number
DZ003197A
Other languages
English (en)
Inventor
Justin Stephen Bryans
David Clive Blakemore
Simon Osborne
Jean-Marie Receveur
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3197A1 publication Critical patent/DZ3197A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
DZ003197A 1999-10-20 2000-10-17 Acides aminés bicycliques utilises comme agents pharmaceutiques. DZ3197A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20
PCT/US2000/028687 WO2001028978A1 (fr) 1999-10-20 2000-10-17 Acides amines bicycliques utilises comme agents pharmaceutiques

Publications (1)

Publication Number Publication Date
DZ3197A1 true DZ3197A1 (fr) 2001-04-26

Family

ID=22578159

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003197A DZ3197A1 (fr) 1999-10-20 2000-10-17 Acides aminés bicycliques utilises comme agents pharmaceutiques.

Country Status (50)

Country Link
US (2) US6689906B1 (fr)
EP (2) EP1226110B1 (fr)
JP (2) JP3632191B2 (fr)
KR (2) KR100593349B1 (fr)
CN (1) CN1165518C (fr)
AP (2) AP2004003186A0 (fr)
AR (2) AR026087A1 (fr)
AT (2) ATE293590T1 (fr)
AU (2) AU778871B2 (fr)
BG (2) BG106719A (fr)
BR (1) BR0014972B1 (fr)
CA (1) CA2386297C (fr)
CO (1) CO5280060A1 (fr)
CR (1) CR6620A (fr)
CU (1) CU23112A3 (fr)
CZ (1) CZ295960B6 (fr)
DE (2) DE60034157T2 (fr)
DO (1) DOP2000000083A (fr)
DZ (1) DZ3197A1 (fr)
EA (1) EA005206B1 (fr)
EC (1) ECSP045393A (fr)
EE (1) EE200200211A (fr)
ES (2) ES2237464T3 (fr)
GE (1) GEP20043297B (fr)
GT (2) GT200000183A (fr)
HK (1) HK1049826B (fr)
HN (1) HN2000000224A (fr)
HR (2) HRP20020428B1 (fr)
HU (1) HUP0203325A3 (fr)
IL (3) IL149143A0 (fr)
IS (2) IS6348A (fr)
MA (1) MA26842A1 (fr)
MX (1) MXPA02003229A (fr)
MY (1) MY127678A (fr)
NO (2) NO20021780L (fr)
NZ (1) NZ517961A (fr)
OA (1) OA12070A (fr)
PA (1) PA8505201A1 (fr)
PE (1) PE20010740A1 (fr)
PL (1) PL354607A1 (fr)
PT (1) PT1226110E (fr)
SI (1) SI1226110T1 (fr)
SK (1) SK5232002A3 (fr)
SV (1) SV2001000188A (fr)
TR (2) TR200201094T2 (fr)
TW (2) TWI225855B (fr)
UA (1) UA72931C2 (fr)
WO (1) WO2001028978A1 (fr)
YU (2) YU29302A (fr)
ZA (1) ZA200202543B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
DK1296671T3 (da) * 2000-06-26 2008-06-16 Warner Lambert Co Gabapentinanaloger til sövnforstyrrelser
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (fr) * 2001-01-26 2002-07-31 Warner-Lambert Company Utilisation d'acides aminés bicycliques pour la prevention et le traitement des douleurs viscérales ainsi que des maladies gastrointestinales
IL157932A0 (en) * 2001-04-19 2004-03-28 Warner Lambert Co Fused bicyclic or tricyclic amino acids
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
EP1469841A1 (fr) * 2002-01-31 2004-10-27 Warner-Lambert Company Ligands alpha 2 delta dans le traitement des acouphenes
WO2003070237A1 (fr) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinaisons d'un ligand alpha-2-delta avec un inhibiteur selectif de cyclooxygenase-2
CN1678298A (zh) * 2002-06-27 2005-10-05 沃纳-兰伯特公司 α2δ配体如加巴喷丁或普瑞巴林用于治疗注意力缺陷的过度反应症的用途
CA2494811A1 (fr) * 2002-08-15 2004-02-26 Pfizer Inc. Utilisation therapeutique d'acides amines bicycliques ou tricycliques
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
WO2004052360A1 (fr) 2002-12-11 2004-06-24 Xenoport, Inc. Promedicaments d'analogues gaba fusionnes, compositions pharmaceutiques, et utilisations correspondantes
RU2353358C2 (ru) 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
DK1572173T3 (da) 2002-12-13 2010-06-14 Warner Lambert Co Alpha-2-delta-ligand til behandling af symptomer i den nedre urinvej
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
KR20090092307A (ko) 2006-12-22 2009-08-31 레코르다티 아일랜드 리미티드 하요도 장애에 대한 α2δ 리간드 및 ＮＳＡＩＤｓ의 복합 치료
JP4479974B2 (ja) 2007-09-28 2010-06-09 第一三共株式会社 二環性γ−アミノ酸誘導体
JP5557292B2 (ja) 2009-03-26 2014-07-23 第一三共株式会社 二環性γ−アミノ酸誘導体の製造方法
ES2649968T3 (es) 2011-06-08 2018-01-16 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto bicíclico vía transposición de Claisen
HUE037046T2 (hu) 2011-06-08 2018-08-28 Daiichi Sankyo Co Ltd Eljárás biciklusos vegyület elõállítására iminium són keresztül
CA2859003C (fr) 2011-12-15 2016-11-01 Daiichi Sankyo Company, Limited Procede de dedoublement optique pour compose bicyclique faisant appel a un catalyseur asymetrique
IN2014DN07923A (fr) 2012-04-10 2015-05-01 Daiichi Sankyo Companyltd
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (fr) 2017-03-16 2018-09-20 Basf Se Dihydroisoxazoles à substitution hétérobicyclique
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
CN1303059C (zh) 1997-10-27 2007-03-07 沃尼尔·朗伯公司 作为药物的环状氨基酸及其衍生物

Also Published As

Publication number Publication date
DE60019628D1 (de) 2005-05-25
IS7497A (is) 2004-10-08
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
IL149143A (en) 2007-02-11
SK5232002A3 (en) 2003-07-01
PA8505201A1 (es) 2002-08-29
CN1165518C (zh) 2004-09-08
ES2237464T3 (es) 2005-08-01
EE200200211A (et) 2003-06-16
TR200500221T2 (tr) 2005-03-21
HRP20040709A2 (en) 2004-12-31
SI1226110T1 (en) 2005-08-31
PE20010740A1 (es) 2001-07-27
CA2386297A1 (fr) 2001-04-26
TW200505824A (en) 2005-02-16
CO5280060A1 (es) 2003-05-30
BG106719A (bg) 2003-02-28
OA12070A (en) 2003-11-10
BR0014972B1 (pt) 2011-09-06
IS6348A (is) 2002-04-17
NO20043663L (no) 2002-04-16
CA2386297C (fr) 2010-02-09
NZ517961A (en) 2002-12-20
NO20021780D0 (no) 2002-04-16
AP2004003186A0 (en) 2004-12-31
HK1049826A1 (en) 2003-05-30
IL164060A0 (en) 2005-12-18
US20040152779A1 (en) 2004-08-05
PT1226110E (pt) 2005-07-29
ECSP045393A (es) 2004-10-23
EA005206B1 (ru) 2004-12-30
AU2005201268A1 (en) 2005-04-21
YU29302A (sh) 2005-06-10
BG108860A (en) 2006-03-31
TWI225855B (en) 2005-01-01
CN1382118A (zh) 2002-11-27
US6835751B2 (en) 2004-12-28
EP1226110A1 (fr) 2002-07-31
ATE293590T1 (de) 2005-05-15
EP1226110B1 (fr) 2005-04-20
HRP20020428A2 (en) 2005-02-28
AP2002002517A0 (en) 2002-06-30
ES2282785T3 (es) 2007-10-16
HK1049826B (zh) 2005-02-25
HRP20020428B1 (en) 2006-02-28
MA26842A1 (fr) 2004-12-20
CU23112A3 (es) 2006-02-27
CZ20021310A3 (cs) 2003-05-14
AU1092001A (en) 2001-04-30
DE60019628T2 (de) 2006-01-19
DE60034157D1 (de) 2007-05-10
AU778871B2 (en) 2004-12-23
AR045456A2 (es) 2005-10-26
CZ295960B6 (cs) 2005-12-14
MY127678A (en) 2006-12-29
KR100593349B1 (ko) 2006-06-26
JP2003512348A (ja) 2003-04-02
HUP0203325A3 (en) 2003-12-29
UA72931C2 (uk) 2005-05-16
HUP0203325A2 (hu) 2003-02-28
MXPA02003229A (es) 2002-09-30
KR20060013701A (ko) 2006-02-13
GT200000183AA (es) 2005-06-17
EP1506955A1 (fr) 2005-02-16
ZA200202543B (en) 2003-09-23
EP1506955B1 (fr) 2007-03-28
ATE358116T1 (de) 2007-04-15
US6689906B1 (en) 2004-02-10
TR200201094T2 (tr) 2002-09-23
SV2001000188A (es) 2001-09-07
CR6620A (es) 2004-02-02
WO2001028978A1 (fr) 2001-04-26
JP3632191B2 (ja) 2005-03-23
KR100566462B1 (ko) 2006-03-31
KR20020040900A (ko) 2002-05-30
PL354607A1 (en) 2004-01-26
AR026087A1 (es) 2002-12-26
IL149143A0 (en) 2002-11-10
BR0014972A (pt) 2002-07-16
DOP2000000083A (es) 2002-03-30
HN2000000224A (es) 2001-04-11
DE60034157T2 (de) 2007-12-13
YU73004A (sh) 2005-11-28
JP3744928B2 (ja) 2006-02-15
JP2005036009A (ja) 2005-02-10
EA200200293A1 (ru) 2002-10-31
NO20021780L (no) 2002-04-16

Similar Documents

Publication Publication Date Title
DZ3197A1 (fr) Acides aminés bicycliques utilises comme agents pharmaceutiques.
DZ3506A1 (fr) Derives de pyrrole utilises comme agents pharmaceutiques
NO20002217D0 (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
ID24654A (id) Formulasi farmasi omeprazola
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DK1212327T3 (da) Pyrazolopyrimidiner som terapeutiske midler
PT1147083E (pt) Derivados de arilpiperazinil-ciclohexilindole para o tratamento da depressao
PT1240172E (pt) Novos acidos aminopropilfosfinicos
NO20016006L (no) Valensplattformmolekyler som innbefatter aminooksygrupper
IT1317741B1 (it) Metodo per la preparazione di 5-cianoftalide.
EE04747B1 (et) Amiini-plaatina komplekside valmistamismeetod
PT1206436E (pt) Retinoides para o tratamento de enfisema
IT1319251B1 (it) Metodo per la preparazione di 5-carbossiftalide.
FR2802423B1 (fr) Compositions pharmaceutiques
IT1311921B1 (it) Composti farmaceutici.
DE69925882D1 (de) Aminosäurederivate als Entzündungshemmende Mittel
DK1227817T3 (da) Ciclesonid-holdigt vandigt farmaceutisk præparat
ID30032A (id) Formulasi farmasi
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20004816D0 (no) Ny farmasøytisk formulering
IT1313660B1 (it) Procedimento stereoselettivo per la preparazione di endo-3-amminoazabicicloalcani.
DK1226110T3 (da) Bicycliske aminosyrer som farmaceutiske midler
DZ2764A1 (fr) Acides indoléalcanoïques substitués.
IT1306195B1 (it) Composizioni cosmetiche ad uso topico comprendenti amminoacidiessenziali.
ITMI991329A0 (it) Procedimento per la preparazione di tetrafluoroalogenobenzeni